Literature DB >> 1911199

Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer.

G J van Oortmarssen1, J D Habbema.   

Abstract

Data from the screening programme in British Columbia are used to test hypotheses about the natural history of cervical cancer, especially about progression and regression of preclinical lesions (dysplasia and carcinoma in situ). Three models are considered. A model without regression does not give an adequate fit of the data (P less than 0.001), and results in an implausible estimate of 33 years for the mean duration of pre-invasive lesions. A model with an equal regression rate at all ages still does not result in a good reproduction of the data. A good fit is achieved for a model with different regression rates in lesions that develop under and over age 34. Under age 34, 84% of the new lesions will regress spontaneously, with a 95% confidence interval of 76-92% regression. Over age 34, we estimate that 40% of the new lesions will regress. The average duration of dysplasia + CIS is 11.8 years, and the sensitivity of the Pap-smear is 80%. It is concluded that a considerable proportion of pre-invasive lesions in young women do not progress. The findings about progression and duration of pre-invasive lesions do not support the still prevailing tendency of frequently making Pap smears in young women.

Entities:  

Mesh:

Year:  1991        PMID: 1911199      PMCID: PMC1977665          DOI: 10.1038/bjc.1991.350

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  [The development and treatment of epitheliomas].

Authors:  H L KOTTMEIER
Journal:  Rev Fr Gynecol Obstet       Date:  1961-12

2.  Diagnostic and treatment procedures induced by cervical cancer screening.

Authors:  M van Ballegooijen; M A Koopmanschap; G J van Oortmarssen; J D Habbema; K T Lubbe; H M van Agt
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

3.  Cervical-cancer screening: attendance and cost-effectiveness.

Authors:  M A Koopmanschap; G J van Oortmarssen; H M van Agt; M van Ballegooijen; J D Habbema; K T Lubbe
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

4.  Two-stage models for the analysis of cancer screening data.

Authors:  R Brookmeyer; N E Day
Journal:  Biometrics       Date:  1987-09       Impact factor: 2.571

Review 5.  Epidemiology of uterine cervical cancer.

Authors:  L A Brinton; J F Fraumeni
Journal:  J Chronic Dis       Date:  1986

6.  Simplified models of screening for chronic disease: estimation procedures from mass screening programmes.

Authors:  N E Day; S D Walter
Journal:  Biometrics       Date:  1984-03       Impact factor: 2.571

Review 7.  Appropriateness of cervical cancer screening.

Authors:  D M Eddy
Journal:  Gynecol Oncol       Date:  1981-10       Impact factor: 5.482

8.  Organisation and results of the cervical cytology screening programme in British Columbia, 1955-85.

Authors:  G H Anderson; D A Boyes; J L Benedet; J C Le Riche; J P Matisic; K C Suen; A J Worth; A Millner; O M Bennett
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-02

9.  Natural history of cervical neoplasia: consistent results obtained by an identification technique.

Authors:  L Gustafsson; H O Adami
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

10.  Cervical cancer screening.

Authors:  G J van Oortmarrsen; J D Habbema
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

View more
  32 in total

1.  Withdrawing low risk women from cervical screening programmes. Conclusions cannot yet be drawn.

Authors:  M E van den Akker-van Marle; M van Ballegooijen; R Boer; G J van Oortmarssen; J D Habbema
Journal:  BMJ       Date:  1999-07-03

2.  Predicting mortality from cervical cancer after negative smear test results.

Authors:  G J van Oortmarssen; J D Habbema; M van Ballegooijen
Journal:  BMJ       Date:  1992-08-22

3.  The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996.

Authors:  S Bulk; F J Van Kemenade; L Rozendaal; C J L M Meijer
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

4.  Point: cervical cancer screening guidelines should consider observational data on screening efficacy in older women.

Authors:  Alison S Rustagi; Aruna Kamineni; Noel S Weiss
Journal:  Am J Epidemiol       Date:  2013-08-21       Impact factor: 4.897

Review 5.  How to evaluate emerging technologies in cervical cancer screening?

Authors:  Marc Arbyn; Guglielmo Ronco; Jack Cuzick; Nicolas Wentzensen; Philip E Castle
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

6.  Chapter 7: Description of MISCAN-lung, the Erasmus MC Lung Cancer microsimulation model for evaluating cancer control interventions.

Authors:  F W Schultz; R Boer; H J de Koning
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

7.  High-grade cervical disease in adolescents with HIV.

Authors:  L Stewart Massad; Charlesnika T Evans; Gypsyamber D'Souza; Teresa Darragh; Howard Minkoff; Donna Henry; Lakshmi Goparaju; Laila I Muderspach; D Heather Watts
Journal:  J Low Genit Tract Dis       Date:  2008-07       Impact factor: 1.925

8.  [Cervical cancer screening: past--present--future].

Authors:  G Breitenecker
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

9.  Development of a goat model for evaluation of withaferin A: Cervical implants for the treatment of cervical intraepithelial neoplasia.

Authors:  Leslie C Sherwood; Farrukh Aqil; Manicka V Vadhanam; Jeyaprakash Jeyabalan; Radha Munagala; David Hoetker; Sanjay Srivastava; Inder P Singh; Scott Cambron; Martin O'Toole; Wendy Spencer; Lynn P Parker; Ramesh C Gupta
Journal:  Exp Mol Pathol       Date:  2017-11-21       Impact factor: 3.362

10.  Incidence of cervical cancer after several negative smear results by age 50: prospective observational study.

Authors:  Matejka Rebolj; Marjolein van Ballegooijen; Elsebeth Lynge; Caspar Looman; Marie-Louise Essink-Bot; Rob Boer; Dik Habbema
Journal:  BMJ       Date:  2009-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.